KalVista (KALV) to be acquired by Chiesi for $27/share: read why EKTERLY’s HAE growth, pediatric data, and key deal/approval ...

After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly ...

Q4 2025 Earnings Call April 28, 2026 8:00 AM EDTCompany ParticipantsJan Keppeler - Head of Investor Relations, Sustainability ...

We are now approaching the midpoint of the 2020s, and the pace of innovation in radiation oncology has never been greater. Advances in artificial ...

Ecopipam, Emalex's investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late- ...

Mansfield refused to go along with the fashion for more generous grading, earning the nickname – in which he revelled – ...

AI-powered therapy notes are transforming mental health documentation by reducing administrative time, supporting compliance, and improving patient care. Clinicians are experiencing measurable time ...

The biotech’s CEO, Dr James McIlroy, says EBX-102-02 could address significant treatment gaps in IBS, which impacts up to 10% of the global population.

For people transitioning from detox to residential addiction treatment in California, Bright Future Recovery has announced ...

Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late- ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

AI-powered tools are streamlining mental health documentation, cutting note-taking time from hours to minutes while improving accuracy and compliance. Clinicians are adopting formats like SOAP and DAP ...